Welcome to our dedicated page for Rapt Therapeutics news (Ticker: RAPT), a resource for investors and traders seeking the latest updates and insights on Rapt Therapeutics stock.
RAPT Therapeutics, Inc. (Nasdaq: RAPT) is a clinical-stage immunology-based biopharmaceutical company, and its news flow reflects the progress and risks of drug development in inflammatory and immunological diseases. Company announcements routinely describe advances in its pipeline, particularly its anti-IgE monoclonal antibody program ozureprubart (formerly RPT904), as well as financial updates and investor outreach activities.
Visitors to this news page can review press releases on key clinical milestones, such as FDA clearance of an Investigational New Drug application, initiation of the prestIgE Phase 2b trial of ozureprubart in IgE-mediated food allergy, and positive topline data from a Phase 2 trial in chronic spontaneous urticaria conducted by partner Shanghai Jeyou Pharmaceutical Co., Ltd. RAPT’s news also highlights how these data compare to existing therapies like omalizumab in terms of dosing intervals and measured endpoints within the reported studies.
RAPT frequently reports quarterly financial results, detailing research and development and general and administrative expenses, net losses and cash, cash equivalents and marketable securities. News items also cover capital-raising events, such as the pricing and completion of underwritten public offerings of common stock, and the company’s estimates regarding how long its capital resources may fund operations based on current plans.
In addition, RAPT issues press releases about participation in healthcare and investor conferences, including major events hosted by firms such as J.P. Morgan, Wells Fargo, Guggenheim, Stifel, TD Cowen, Cantor and H.C. Wainwright. These updates indicate when management will present company overviews or fireside chats and how investors can access related webcasts or archived presentations.
For investors and observers following RAPT, this news feed provides a consolidated view of clinical trial developments, regulatory interactions, financial disclosures and corporate events that shape the company’s progress in developing therapies for inflammatory and immunological diseases.
RAPT Therapeutics (Nasdaq: RAPT) will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference. Brian Wong, M.D., Ph.D., President and CEO, is scheduled to present on Wednesday, January 14, 2026 at 2:15 p.m. PT. Investors can access a live webcast and an archived recording via the company’s investor website.
This presentation is a corporate overview at a major industry conference and does not include new financial guidance or clinical readouts in the announcement.
RAPT (Nasdaq: RAPT) reported Q3 2025 results and program updates on Nov 6, 2025. Key clinical and financing highlights include FDA clearance of an IND to start a Phase 2b prestIgE trial of ozureprubart in food allergy and initiation of that randomized, placebo-controlled study evaluating Q8W and Q12W dosing.
RAPT and Shanghai Jeyou reported positive topline Phase 2 CSU data showing ozureprubart Q8W and Q12W had comparable efficacy and safety to omalizumab Q4W. The company completed an underwritten public offering raising $250.0M gross and expects cash to fund operations to mid-2028.
RAPT Therapeutics (Nasdaq: RAPT) said members of management will participate in three investor conferences in November 2025: Guggenheim's 2nd Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and TD Cowen Virtual Immunology & Inflammation Summit.
Each participation is a fireside chat on consecutive days: Nov 11, 2025 at 3:30 p.m. ET, Nov 12, 2025 at 2:40 p.m. ET, and Nov 13, 2025 at 2:30 p.m. ET. Live webcasts and archived recordings will be available at https://investors.rapt.com/events-and-presentations.
RAPT (Nasdaq: RAPT) initiated the randomized, double-blind, placebo-controlled prestIgE Phase 2b trial of ozureprubart (RPT904) in IgE-mediated food allergy on Oct 27, 2025. The study will run at approximately 30 sites across the U.S., Canada and Australia and tests two dosing regimens (subcutaneous every 8 weeks or every 12 weeks, with a loading dose) versus placebo in a 2:2:1 ratio.
Part 1 will treat ~100 participants with at least one food allergy (peanut, milk, egg, walnut or cashew) for 24 weeks with a primary endpoint measured by DBPCFC at Week 24. Part 2 continues treatment to Week 48 with a DBPCFC at Week 48 and a 16-week safety follow-up. The program follows prior promising Phase 2 data in chronic spontaneous urticaria and positions ozureprubart as a long‑acting anti‑IgE bio‑better targeting the same epitope as omalizumab.
RAPT Therapeutics (Nasdaq: RAPT) priced an underwritten public offering of 8,333,334 common shares at $30.00 per share, with expected gross proceeds of approximately $250.0 million before fees. The company granted underwriters a 30-day option to purchase up to an additional 1,250,000 shares at the public offering price, less discounts and commissions.
The offering is expected to close on or about October 23, 2025, subject to customary closing conditions, and is being conducted under a shelf registration declared effective by the SEC on August 17, 2023. Joint bookrunning managers and lead managers were named and a final prospectus supplement will be filed with the SEC.
RAPT Therapeutics (Nasdaq: RAPT) announced on October 21, 2025 that it has commenced an underwritten public offering of common stock. The company said it expects to grant underwriters a 30-day option to buy up to an additional 15% of the shares at the public offering price, less underwriting discounts and commissions.
The offering is subject to market conditions and may be completed only by means of a prospectus supplement filed with the SEC; all shares are being offered by RAPT.
RAPT (Nasdaq: RAPT) and Shanghai Jeyou announced positive topline Phase 2 results for RPT904 (JYB1904) in chronic spontaneous urticaria (CSU) on Oct 20, 2025. In a randomized, double-blind 137-patient study, RPT904 dosed every 8 weeks (Q8W) or 12 weeks (Q12W) produced numerically greater UAS7 reductions and higher proportions of patients with UAS7=0 at Weeks 8, 12 and 16 versus omalizumab dosed Q4W. RPT904 showed durability to Week 16 after a single dose and was well tolerated with no serious adverse events related to study drug. Jeyou will advance RPT904 to Phase 3 in China; RAPT will discuss a Phase 3 path with the FDA and host a conference call on Oct 20, 2025.
RAPT Therapeutics (Nasdaq: RAPT) announced it will report topline data from the Phase 2 trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria (CSU) on October 20, 2025.
The data were generated by partner Shanghai Jeyou Pharmaceutical. RAPT will host a webcast and conference call with slides on Monday, October 20, 2025 at 8:30 a.m. ET. Investors may pre-register for phone participation to join live Q&A and can access the live webcast and audio archive via RAPT's investor website at https://investors.rapt.com/events-and-presentations.
RAPT Therapeutics (Nasdaq: RAPT) has received FDA clearance for its Investigational New Drug (IND) Application to proceed with a Phase 2b clinical trial of RPT904 for food allergy treatment. The trial will be a randomized, double-blind, placebo-controlled study evaluating RPT904's safety and efficacy with dosing intervals of 8 and 12 weeks.
The company plans to initiate the trial by the end of 2025. RPT904 is RAPT's next-generation, half-life extended anti-IgE molecule. Additional data from RAPT's Chinese partner Jeyou's Phase 2 trials in chronic spontaneous urticaria and asthma is expected by year-end.
RAPT Therapeutics (NASDAQ: RAPT), a clinical-stage biopharmaceutical company specializing in immunology-based therapies, has announced its participation in four major investor conferences in September 2025.
The company will present at the Wells Fargo Healthcare Conference (Sept 3), Cantor Global Healthcare Conference (Sept 4), H.C. Wainwright Global Investment Conference (Sept 9), and Stifel Virtual Immunology & Inflammation Forum (Sept 15). All presentations will be accessible via webcast on the company's investor relations website.